Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of “Reduce” from Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has been given an average recommendation of “Reduce” by the ten brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $5.10.

A number of analysts have recently commented on DH shares. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, June 21st. BTIG Research lowered shares of Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group upped their price objective on shares of Definitive Healthcare from $3.00 to $3.40 and gave the stock a “neutral” rating in a research report on Monday, May 12th.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $4.02 on Thursday. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $6.16. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company has a market cap of $597.53 million, a PE ratio of -0.92, a price-to-earnings-growth ratio of 6.65 and a beta of 1.64. The company’s 50 day moving average is $3.65 and its 200 day moving average is $3.64.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $59.19 million during the quarter, compared to the consensus estimate of $56.20 million. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The firm’s quarterly revenue was down 6.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 earnings per share. On average, sell-side analysts forecast that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in Definitive Healthcare by 35.9% during the 4th quarter. Bank of New York Mellon Corp now owns 229,143 shares of the company’s stock worth $942,000 after acquiring an additional 60,559 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Definitive Healthcare by 928.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 156,997 shares of the company’s stock worth $645,000 after purchasing an additional 141,729 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Definitive Healthcare by 28.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 146,623 shares of the company’s stock worth $603,000 after purchasing an additional 32,071 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Definitive Healthcare by 166.1% in the fourth quarter. Intech Investment Management LLC now owns 32,979 shares of the company’s stock valued at $136,000 after purchasing an additional 20,586 shares during the period. Finally, Quantbot Technologies LP boosted its stake in shares of Definitive Healthcare by 5,305.5% in the fourth quarter. Quantbot Technologies LP now owns 17,730 shares of the company’s stock valued at $73,000 after purchasing an additional 17,402 shares during the period. 98.67% of the stock is owned by hedge funds and other institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.